Frequently Asked Questions about Can-Fite BioPharma Ltd. (CANF)

Name: Can-Fite BioPharma Ltd. (CANF) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Can-Fite BioPharma Ltd. (CANF) do?

Accepted Answer

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for ...

Question 2

Is Can-Fite BioPharma Ltd. (CANF) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of CANF reveals an Altman Z-Score of -27.87 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if CANF fits their risk profile.

Question 3

What is the current P/E ratio for CANF?

Accepted Answer

As of the latest trading session, Can-Fite BioPharma Ltd. (CANF) has a trailing P/E ratio of -800.10.

Question 4

Who is the CEO of Can-Fite BioPharma Ltd.?

Accepted Answer

The current Chief Executive Officer of Can-Fite BioPharma Ltd. is Pnina Fishman.

Question 5

What was CANF's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Can-Fite BioPharma Ltd. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does CANF pay a dividend?

Accepted Answer

Can-Fite BioPharma Ltd. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does CANF have?

Accepted Answer

In its latest reporting period, Can-Fite BioPharma Ltd. generated $-0.01B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Can-Fite BioPharma Ltd.?

Accepted Answer

The Price-to-Book (P/B) ratio for Can-Fite BioPharma Ltd. (CANF) is currently 978.31.

Question 9

What is the Price-to-Sales (P/S) ratio of CANF?

Accepted Answer

Based on trailing twelve-month data, Can-Fite BioPharma Ltd. (CANF) trades at a Price-to-Sales (P/S) ratio of 21538.30.

Question 10

What is Can-Fite BioPharma Ltd.'s Return on Equity (ROE)?

Accepted Answer

Can-Fite BioPharma Ltd. (CANF) has a Return on Equity (ROE) of -141.01%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-9M	0	-2K	-9M	-9M
2024-12	-7.6M	362K	-5K	-7.6M	-8M
2023-12	-8.4M	261K	-2K	-8.4M	-8.7M
2022-12	-10.8M	263K	-9K	-10.8M	-11.1M
2021-12	-9.9M	466K	-11K	-9.9M	-10.3M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-9M	0	-2K	-9M	-9M
2024-12	-7.6M	362K	-5K	-7.6M	-8M
2023-12	-8.4M	261K	-2K	-8.4M	-8.7M
2022-12	-10.8M	263K	-9K	-10.8M	-11.1M
2021-12	-9.9M	466K	-11K	-9.9M	-10.3M